Vol 10, Supplement 13 (May 29, 2018): Journal of Thoracic Disease (Immunotherapy & Thoracic Cancers)

Preface

Immunotherapy & thoracic cancers

Antonio Rossi, Silvia Novello

PDF Pages: S1425-S1426 Full Text (1181) Open Access

Review Article

Is there a room for immune checkpoint inhibitors in early stage non-small cell lung cancer?

Elisa Gobbini, Matteo Giaj Levra

PDF Pages: S1427-S1437 Full Text (3077) Open Access

The role of radiology in the evaluation of the immunotherapy efficacy

Marco Calandri, Federica Solitro, Valeria Angelino, Federica Moretti, Andrea Veltri

PDF Pages: S1438-S1446 Full Text (4949) Open Access

Combining immunotherapy and radiotherapy in lung cancer

Neeraj Bhalla, Rachel Brooker, Michael Brada

PDF Pages: S1447-S1460 Full Text (4376) Open Access

Locally-advanced non-small cell lung cancer: shall immunotherapy be a new chance?

Andrea Riccardo Filippi, Jacopo Di Muzio, Serena Badellino, Cristina Mantovani, Umberto Ricardi

PDF Pages: S1461-S1467 Full Text (2042) Open Access

Advanced non-small cell lung cancer: the role of PD-L1 inhibitors

David F. Heigener, Martin Reck

PDF Pages: S1468-S1473 Full Text (2695) Open Access

Lung cancer, elderly and immune checkpoint inhibitors

Francesca Casaluce, Assunta Sgambato, Paolo Maione, Alessia Spagnuolo, Cesare Gridelli

PDF Pages: S1474-S1481 Full Text (3296) Open Access

Immunotherapy in the Asiatic population: any differences from Caucasian population?

Lunxi Peng, Yi-Long Wu

PDF Pages: S1482-S1493 Full Text (3079) Open Access

Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios

Rebecca Tay, Arsela Prelaj, Raffaele Califano

PDF Pages: S1494-S1502 Full Text (3442) Open Access

Immune checkpoint inhibitors and small cell lung cancer: what’s new?

Sabine Schmid, Martin Früh

PDF Pages: S1503-S1508 Full Text (3288) Open Access

Thymic tumors and immune checkpoint inhibitors

Shintaro Yokoyama, Hiroaki Miyoshi

PDF Pages: S1509-S1515 Full Text (2256) Open Access

Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients

Jordi Remon, Laura Mezquita, Jesús Corral, Noelia Vilariño, Noemi Reguart

PDF Pages: S1516-S1533 Full Text (6296) Open Access

Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors

Meng Qiao, Tao Jiang, Caicun Zhou

PDF Pages: S1534-S1546 Full Text (2007) Open Access

Oncogene-addicted non-small cell lung cancer and immunotherapy

Georgios Tsakonas, Simon Ekman

PDF Pages: S1547-S1555 Full Text (4714) Open Access

A review of guidelines for lung cancer

Paolo Bironzo, Massimo Di Maio

PDF Pages: S1556-S1563 Full Text (5099) Open Access

Do immune checkpoint inhibitors need new studies methodology?

Roberto Ferrara, Sara Pilotto, Mario Caccese, Giulia Grizzi, Isabella Sperduti, Diana Giannarelli, Michele Milella, Benjamin Besse, Giampaolo Tortora, Emilio Bria

PDF Pages: S1564-S1580 Full Text (5105) Open Access

Next generation immune-checkpoints for cancer therapy

Chiara Donini, Lorenzo D’Ambrosio, Giovanni Grignani, Massimo Aglietta, Dario Sangiolo

PDF Pages: S1581-S1601 Full Text (5589) Open Access

Vaccine and immune cell therapy in non-small cell lung cancer

Helena Oliveres, Christian Caglevic, Francesco Passiglia, Simona Taverna, Evelien Smits, Christian Rolfo

PDF Pages: S1602-S1614 Full Text (3975) Open Access

Disclosure:

The supplement “Immunotherapy & Thoracic Cancers” was commissioned by the Editorial office, Journal of Thoracic Disease without any sponsorship or funding. Antonio Rossi and Silvia Novello served as the unpaid Guest Editors for the supplement.